Elicio Therapeutics Enters Material Definitive Agreement

TL;DR

Elicio Therapeutics just signed a big deal, filing an 8-K for a material definitive agreement.

AI Summary

Elicio Therapeutics, Inc. announced on January 29, 2025, that it entered into a material definitive agreement. The company, formerly known as Angion Biomedica Corp. until February 28, 2014, is incorporated in Delaware and headquartered in Boston, MA. This filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing indicates a significant new contract or partnership for Elicio Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms of the agreement, counterparty performance, and potential impact on the company's strategic direction.

Key Numbers

• 001-39990 — SEC File Number (Identifies the company's filing with the SEC.)
• 11-3430072 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Elicio Therapeutics, Inc. (company) — Registrant
• Angion Biomedica Corp. (company) — Former company name
• January 29, 2025 (date) — Date of earliest event reported
• 001-39990 (company) — SEC File Number
• 11-3430072 (company) — IRS Employer Identification No.
• Boston, Massachusetts (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.01 — ge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq
• $7.925 — ogether at a combined offering price of $7.925. The Common Warrants have an exercise p
• $7.80 — mmon Warrants have an exercise price of $7.80 per share, are immediately exercisable
• $10 million — ny from the Offering were approximately $10 million before deducting the placement agent's
• $35,000 — a non-accountable expense allowance of $35,000, (iii) reimbursement of up to $50,000 f
• $50,000 — f $35,000, (iii) reimbursement of up to $50,000 for legal fees and expenses and other o
• $15,950 — r out of pocket expenses and (iv) up to $15,950 for the clearing expenses. The Offeri

Filing Documents

• d914999d8k.htm (8-K) — 32KB
• d914999dex41.htm (EX-4.1) — 69KB
• d914999dex51.htm (EX-5.1) — 11KB
• d914999dex101.htm (EX-10.1) — 171KB
• d914999dex991.htm (EX-99.1) — 10KB
• g914999dsp5.jpg (GRAPHIC) — 6KB
• g914999dsp6.jpg (GRAPHIC) — 4KB
• 0001193125-25-016455.txt ( ) — 512KB
• eltx-20250129.xsd (EX-101.SCH) — 3KB
• eltx-20250129_lab.xml (EX-101.LAB) — 18KB
• eltx-20250129_pre.xml (EX-101.PRE) — 11KB
• d914999d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 4.1 Form of Common Warrant. 5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 10.1 Form of Securities Purchase Agreement, dated as of January 29, 2025, by and among Elicio Therapeutics, Inc. and the purchasers party thereto. 23.1 Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1). 99.1 Pricing Press Release, dated January 30, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Robert Connelly President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer) Date: January 30, 2025

View Full Filing

View this 8-K filing on SEC EDGAR